CellSave Arabia, a leading stem cell bank in the GCC region, proudly announces its achievement of the AABB (Association for the Advancement of Blood & Biotherapies) accreditation for cellular therapy activities, marking a significant milestone in the field of regenerative medicine.
Since its inception in 2005, CellSave Arabia has been at the forefront of innovation, setting benchmarks in stem cell banking and therapeutic applications. In 2008, the company made history by becoming the inaugural stem cell laboratory in the region to secure AABB accreditation for Cord Blood Services, marking a pivotal moment in advancing healthcare standards.
Building upon its legacy of excellence, CellSave Arabia has once again made history by being re-accredited for Cord Blood Services and, notably, achieving AABB accreditation for Somatic Cell Services, covering the procurement, processing, storing, and distribution of somatic cell products, including cord tissue and placenta tissue. This dual accreditation underscores CellSave Arabia’s unwavering commitment to maintaining the highest standards of quality, safety, and efficacy across all aspects of cellular therapy. Furthermore, CellSave Arabia holds FDA registration for the collection, processing, storing, and distribution of both Cord Blood and somatic cells (cord tissue and placenta), further solidifying its adherence to international regulatory standards and commitment to excellence.
“Being recognized as the first stem cell bank in the GCC region to achieve AABB accreditation for both Cord Blood and Somatic Cell Services is a testament to our dedication to advancing healthcare standards,” remarked Sarah Al-Hajali, CEO of CellSave Arabia. “This milestone reinforces our position as a trusted leader in the field and underscores our ongoing commitment to delivering cutting-edge solutions and life-changing therapies to our clients.”
Undergoing rigorous evaluation by AABB assessors, CellSave Arabia’s facilities, procedures, and quality management systems have met and surpassed the stringent requirements set forth by the accrediting body. By attaining dual accreditation, CellSave Arabia solidifies its position as a frontrunner in stem cell banking and regenerative medicine in the GCC region.
With over 80 successful transplant releases in 2023 alone, CellSave Arabia continues to make significant strides in advancing healthcare outcomes and empowering individuals with state-of-the-art solutions for their medical needs. As the company looks towards the future, it remains steadfast in its commitment to pushing the boundaries of cellular therapy and driving positive change in healthcare.
